Emerging Weight-Loss Drugs Spark Excitement and Competition in Retail Market

Retail investors have flocked to buy shares of Eli Lilly after the U.S. pharmaceutical company received approval for its weight-loss drug, Zepbound. Daily net purchases reached a more than two-year high of $14.4 million on November 8, signaling a resurgence of interest in the healthcare sector. Eli Lilly and Novo Nordisk, both leaders in the potential $100 billion obesity treatment market, have attracted retail investors who are now catching up with institutional investors. Despite a decline in overall retail flows to U.S. exchanges, interest in weight-loss drugmakers remains strong.